Laryngeal Neoplasms  >>  Erbitux (cetuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
DeLOS II, NCT00508664: Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
180
Europe
Radiation, Cetuximab, Docetaxel, Taxotere, Cisplatin (TP), 5-Fluorouracil (TPF) (only until Feb 2009)
ClinAssess, Merck Sharp & Dohme LLC, Sanofi
Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma
02/15
02/15

Download Options